MX2023000261A - 1-[1-(4-benciloxi-3,5-difluoro-benzoil)-4-fluoro-pirrolidin-2-car bonil]-pirrolidin-2-carbonitrilo. - Google Patents

1-[1-(4-benciloxi-3,5-difluoro-benzoil)-4-fluoro-pirrolidin-2-car bonil]-pirrolidin-2-carbonitrilo.

Info

Publication number
MX2023000261A
MX2023000261A MX2023000261A MX2023000261A MX2023000261A MX 2023000261 A MX2023000261 A MX 2023000261A MX 2023000261 A MX2023000261 A MX 2023000261A MX 2023000261 A MX2023000261 A MX 2023000261A MX 2023000261 A MX2023000261 A MX 2023000261A
Authority
MX
Mexico
Prior art keywords
pyrrolidine
benzyloxy
difluoro
benzoyl
fluoro
Prior art date
Application number
MX2023000261A
Other languages
English (en)
Spanish (es)
Inventor
Clua Teresa Tarragó
Cosano Roger Prades
Original Assignee
Accure Therapeutics S L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Accure Therapeutics S L filed Critical Accure Therapeutics S L
Publication of MX2023000261A publication Critical patent/MX2023000261A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
MX2023000261A 2020-07-07 2021-07-06 1-[1-(4-benciloxi-3,5-difluoro-benzoil)-4-fluoro-pirrolidin-2-car bonil]-pirrolidin-2-carbonitrilo. MX2023000261A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20382606 2020-07-07
PCT/EP2021/068577 WO2022008477A1 (en) 2020-07-07 2021-07-06 1-[1-(4-benzyloxy-3,5-difluoro-benzoyl)-4-fluoro-pyrrolidine-2-carbonyl]-pyrrolidine-2-carbonitrile

Publications (1)

Publication Number Publication Date
MX2023000261A true MX2023000261A (es) 2023-04-13

Family

ID=71607883

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023000261A MX2023000261A (es) 2020-07-07 2021-07-06 1-[1-(4-benciloxi-3,5-difluoro-benzoil)-4-fluoro-pirrolidin-2-car bonil]-pirrolidin-2-carbonitrilo.

Country Status (19)

Country Link
US (1) US12459891B2 (enExample)
EP (1) EP4178945B1 (enExample)
JP (1) JP7628716B2 (enExample)
KR (1) KR20230035604A (enExample)
CN (1) CN117545738A (enExample)
AU (1) AU2021303440A1 (enExample)
BR (1) BR112023000335A2 (enExample)
CA (1) CA3185064A1 (enExample)
ES (1) ES2997164T3 (enExample)
HR (1) HRP20241527T1 (enExample)
HU (1) HUE068953T2 (enExample)
IL (1) IL299035B1 (enExample)
MA (1) MA60250B1 (enExample)
MX (1) MX2023000261A (enExample)
RS (1) RS66215B1 (enExample)
SM (1) SMT202400460T1 (enExample)
TW (1) TWI893162B (enExample)
WO (1) WO2022008477A1 (enExample)
ZA (1) ZA202213708B (enExample)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6159938A (en) 1994-11-21 2000-12-12 Cortech, Inc. Serine protease inhibitors comprising α-keto heterocycles
DE19603510A1 (de) 1996-02-01 1997-08-07 Knoell Hans Forschung Ev Die Verwendung von Terrecyclolsäure A und Terrecyclolsäure A-Derivate als neue Inhibitoren der humanen Prolyl-Oligopeptidase
FI20011466A0 (fi) 2001-07-04 2001-07-04 Orion Corp Prolyylioligopeptidaasia inhiboivaa aktiivisuutta omaavia yhdisteitä, niiden valmistusmenetelmiä ja käyttö
FI20030014A0 (fi) 2003-01-03 2003-01-03 Orion Corp Prolyylioligopeptidaasia inhiboivaa aktiivisuutta omaavia yhdisteitä
FI20031018A0 (fi) 2003-07-04 2003-07-04 Orion Corp Parannus aivovammasta toipumiseen
WO2005027934A1 (ja) 2003-09-24 2005-03-31 Nippon Kayaku Kabushiki Kaisha プロリルオリゴペプチダーゼ阻害剤
US7667044B2 (en) 2003-11-03 2010-02-23 Probiodrug Ag Compounds for the treatment of neurological disorders
ES2302473B1 (es) 2006-12-22 2009-06-12 Universidad De Barcelona Agente terapeutico para el tratamiento del desorden afectivo bipolar en mamiferos.
EP2730571A1 (en) * 2012-11-12 2014-05-14 Universitat De Barcelona 1-[1-(benzoyl)-pyrrolidine-2-carbonyl]-pyrrolidine-2-carbonitrile derivatives

Also Published As

Publication number Publication date
ZA202213708B (en) 2024-04-24
IL299035A (en) 2023-02-01
TWI893162B (zh) 2025-08-11
JP7628716B2 (ja) 2025-02-12
SMT202400460T1 (it) 2025-01-14
EP4178945B1 (en) 2024-08-28
BR112023000335A2 (pt) 2023-01-31
US12459891B2 (en) 2025-11-04
AU2021303440A1 (en) 2023-02-02
CN117545738A (zh) 2024-02-09
EP4178945C0 (en) 2024-08-28
US20230250058A1 (en) 2023-08-10
WO2022008477A1 (en) 2022-01-13
ES2997164T3 (en) 2025-02-14
EP4178945A1 (en) 2023-05-17
CA3185064A1 (en) 2022-01-13
HUE068953T2 (hu) 2025-02-28
JP2023533932A (ja) 2023-08-07
MA60250B1 (fr) 2024-11-29
TW202216689A (zh) 2022-05-01
KR20230035604A (ko) 2023-03-14
HRP20241527T1 (hr) 2025-01-03
IL299035B1 (en) 2026-03-01
RS66215B1 (sr) 2024-12-31

Similar Documents

Publication Publication Date Title
ZA202300924B (en) Quinoxaline derivatives as anti-cancer drugs
MX2023007497A (es) Nuevos derivados de quinazolina como inhibidores de sos1 y uso de los mismos.
GEP20257823B (en) Amino quinazoline derivatives as p2x3 inhibitors
PH12022553019A1 (en) Il-17a modulators
BR112015019720B8 (pt) Inibidores de (benzil-ciano-metil)-amidas de ácido 2-azabiciclo[2.2.1]heptano-3-carboxílico substituído da catepsina c e composição farmacêutica
PH12022500021A1 (en) Il-17a modulators
ZA202211464B (en) Tetrahydroisoquinoline compounds as nrf2 activators
NZ737536A (en) Substituted benzamides and methods of use thereof
PH12018502337A1 (en) Tetrahydropyrimidodiazepine and tetrahydropyridodiazepine compounds for treating pain and pain related conditions
CA2890042C (en) 1-[1-(benzoyl)-pyrrolidine-2-carbonyl]-pyrrolidine-2-carbonitrile derivatives
MX2023011864A (es) Inhibidores de dihidroorotato deshidrogenasa deuterados.
GEAP202415866A (en) 3,6-diamino-pyridazin-3-yl derivatives, pharmaceutical compositions containing them and their uses as pro-apoptotic agents
ZA202211465B (en) Tetrahydroisoquinoline compounds as nrf2 activators
MX2024008910A (es) Farmaceutico para tratamiento de infeccion de nuevo coronavirus.
ZA202213708B (en) 1-[1-(4-benzyloxy-3,5-difluoro-benzoyl)-4-fluoro-pyrrolidine-2-carbonyl]-pyrrolidine-2-carbonitrile
GEP20267853B (en) Bicyclic heteroaromatic inhibitors of klk5
MX2022007175A (es) Compuestos y su uso para el tratamiento de la deficiencia de a1-antitripsina.
CR20210605A (es) N-(prid-3-il)carboxamidas fungicidas
AR127031A1 (es) Derivados de 3-fenoxiazetidin-1-il-heteroaril pirrolidina y el uso de estos como medicamento
JOP20250156A1 (ar) تركيبة صيدلانية تشتمل على إينافوجليفلوزين وميتفورمين
JOP20240175A1 (ar) مركبات بيرازولو بيريميدين، وتركيبات تشتمل عليها واستخداماتها
PH12020550594A1 (en) New alcoxyamino derivatives for treating pain and pain related conditions
PH12021552324A1 (en) Carbamoyl cyclohexane derivatives for treating autism spectrum disorder
MX2024011524A (es) Derivado de heteroarilo y uso del mismo.
MX2021013771A (es) Compuestos inhibidores del intercambiador de sodio-hidrogeno 3.